Kidney Week 2015

Sucroferric Oxyhydroxide Safe and Well-Tolerated in the Long-Term

San Diego—In hemodialysis patients in Japan, PA21 (sucroferric oxyhydroxide [SFOH]) was well tolerated in the long term and had a low pill burden. That was among the findings of an open-label, multicenter study conducted in Japan to assess the long-term safety and efficacy of SFOH following a 52-week treatment period. Fumihiko Koiwa, MD, PhD, and colleagues presented results of the ... Read More »

Sevelamer Improves Oxidative Stress in Hemodialysis Patients

San Diego—Oxidative stress was improved in patients on maintenance hemodialysis with the use of sevelamer hydrochloride in a study conducted recently by Siren Sezer, MD, and colleagues. Study results were presented during a poster session at Kidney Week 2015 in a poster titled Sevelamer Hydrochloride Improves Oxidative Stress in Maintenance Hemodialysis Patients. Oxidative stress has an important role in the ... Read More »

Long Dialysis Recovery Time and Fluid Management

San Diego—A large proportion of patients on conventional hemodialysis face long dialysis recovery time, which is associated with increased mortality and shorter time to hospitalization. Wael F. Hussein, MD, and colleagues recently conducted a study to examine the association of fluid management and hemodynamics with recovery time in conventional hemodialysis patients. The researchers reported results of the study during a ... Read More »

Enzyme Replacement Therapy in Older Patients with Fabry Disease

San Diego—Despite enzyme replacement therapy, older patients in Canada with Fabry disease experience clinical events but seem to be living longer. That was among the findings of a comparison of outcomes of enzyme replacement therapy in patients >65 years of age compared with the overall Canadian Fabry Disease Initiative (CFDI) population. Michael L. West, BSc, FRCPC, FACP, and colleagues reported ... Read More »

Patient-Centric Automated Peritoneal Dialysis Cycler Rated Higher than Conventional Cycler

San Diego—Automated peritoneal dialysis (APD), a therapy for patients with end-stage renal disease (ESRD), is currently underutilized, due perhaps to the perception that patients may not be able to manage treatment setups, a skill required with that treatment modality. Some barriers to uptake of APD many be reduced via improvements to cycler technology that may futher simplify therapy procedures for ... Read More »

AMG 416 Safe after Discontinuation of Cinacalcet

San Diego—Significant decreases in parathyroid hormone (PTH) with no increase in serum phosphate or in albumin-adjusted serum calcium have been shown in two previous 26-week placebo-controlled randomized clinical trials with AMG 416, a novel intravenous calcimimetic agent. Kenneth Liss, DO, and colleagues recently conducted a 4-week, multiple-dose single-arm, open-label safety study designed to assess the incidence of hypocalcemia in patients ... Read More »

Peritoneal Dialysis Therapy Prescription Adequacy Predicted with Standard and Fast PET

San Diego—The fast peritoneal equilibration test (PET) is used to determine peritoneal membrane transport status. However, there are few data quantifying the accuracy of using PET to predict parameters of peritoneal dialysis therapy. Researchers recently conducted a study designed to examine the ability of a new version of PD Adequest, a computer software program, to (1) compare mass transfer-area coefficients ... Read More »

Sucroferric Oxyhydroxide Reduces Pill Burden Compared to Sevelamer

San Diego—In a study conducted among Japanese hemodialysis patients with hyperphosphatemia, PA 21 (sucroferric oxyhydroxide [SFOH]) showed a significant serum phosphorus reduction compared with sevelamer hydrochloride (HCI). That was among the findings of a randomized, open-label, parallel-group, multicenter, active-controlled phase 3 study reported during a poster session at Kidney Week 2015. Fumihiko Koiwa, MD, PhD, and colleagues reported the study ... Read More »